FORMULATION, DEVELOPMENT AND IN VITRO EVALUATION OF SILDENAFIL CITRATE LIGNOCAINE HCl GEL

Authors

  • Dhananjay Patil Department of Pharmaceutics, KBHSS Trust Institute of Pharmacy, Malegaon Camp, Nashik, Maharashtra, India

Abstract

In limited resource countries, the effectiveness of first-line antiretroviral treatment in HIV-positive patients could be measured by its strong predictor, the CD4 count for the initiation of antiretroviral therapy and proper management of disease progress. Even though, in addition to HIV, there are many factors which can influence the CD4 cell count considered to be constant. Methods: A retrospective cohort study was conducted to examine the response of first-line antiretroviral treatment on CD4 count in HIV-positive patients at 0, 6, 12 and 24 months, who enrolled in the first month of 2013 and followed up to begining-2018.The covariance components model was employed to determine the CD4 count changes over time. Results: A total of 320 ART attendants were used to analyze their data. The majority 294(92.4%) of the respondents were started AZT based ART regimens, but there was no a significance difference among ART regimens for CD4 cell count. The mean baseline of CD4 cell count (166 cells/ mm3) was positive associated (p<0.001) with CD4 count increment at time of follow ups and was increased to 274 cells/mm3 significantly (p<0.001) at six months of initiation of ART. Working functional status and younger age, also contribute for CD4 count significant change. Conclusion:  The change in CD4 count was high at the first 6 month than 12 and 24 month.  All ART regimens without significance difference that increased mean CD4 count at the study period. Hence, it can be concluded that ART is effective enough in improving the immune system and slowing the progression of HIV infection to AIDS.

Keywords:  CD4 count, ART, Boru meda hospital

References

Control CfD. Centers for Disease Control and Prevention.2003

Markowitz SB. Environmental and occupational medicine. Wolters Kluwer/Lippincott Williams & Wilkins; 2007

National Centre for AIDS & STD Control .National anti-retroviral therapy guidelines, Government of Nepal, Ministry of Health & Population; 2009

R Chris Rathbun, PharmD, BCPS, AQ-ID, AAHIVE Antiretroviral Therapy for HIV Infection ; 2013

F. J. J. Palella, K. M. Delaney, A. C.Moorman et al., “Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators,”The New England Journal ofMedicine; 1998, 338(13), pp. 853–860,

K. Suresh Babu, Ch. Ram Babu, N. Baratha Jyothi and K. Sunita. A retrospective study on status of CD4 counts and effect of ART in patients attending VCTC of MGM Hospital, Warangal, Andhra Pradesh, India, IOSR Journal of Nursing and Health Science;2014, 3(6 ),2320–1940.

Lemma Derseh Gezie.Predictors of CD4 count over time among HIV patients initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia: multilevel analysis, BMC Research Notes ;2016, 9:377

Denis Nash, Monica Katyal, Martin W.G. Brinkhof et al Long-term immunologic response to antiretroviral therapy in low-income countries: Collaborative analysis of prospective studies AIDS.;2008, 22(17): 2291–2302

Palmer BE, Boritz E, Blyveis N, Wilson CC: Discordance between frequencies of human Immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-producing CD4 (+) T cells. And HIV-1-specific lymphoproliferation in HIV-1-infected subjects with active viral Replication Virol;2002, 76(12):5925–5936.

European collaborative study material history of vertically acquired human Immunodeficiency virus infection pediatrics 1994; 94:815-819

Kwobach CM, Braitstein P, Koech JK, Simiyu G, Mwanqi AW, Siika AM et al. Factors associated with late engagement to HIV care in Western Kenya: a cross-sectional study. J Int Assoc Provid AIDS Care. 2015.

Mojumdar K, Vajpayee M, Chauhan N, Mendiratta S. Late presenters to HIV care and treatment, identification of associated risk factors in HIV-1 infected Indian population. BMC Public Health. 2010;10:416.

Addisu A, Dagim A, Tadele E, Adissu A, Mussie A, Filmon K. CD4 cell count trends after commencement of antiretroviral therapy among HIV infected patients in Tigray, northern Ethiopia: a retrospective cross-sectional study. PLoS ONE. 2015;10(3).

Galdas PM, Cheater F, Marshall P. Men and health help-seeking behaviour:l iterature review. J Adv Nurs; 2005;49(6):616–23.

Cornell M, Schomaker M, Garone DB, Giddy J, Hoffmann CJ, Lessells R, et al. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study. PLoS Med; 2012, 9

Madec Y, Laureillard D, Pinoges L, Fernandez M, Prak N, Ngeth C, et al. Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia. AIDS 2007, 21:351–359.

MacPherson P, Moshabela M, Martinson N, Pronyk P. Mortality and loss to follow-up among HAART initiators in rural South Africa. Trans R Soc Trop Med Hyg; 2009, 103:588–593.

Majid D, Leigh A. Shaferc, S C, Ken K, Yoav K. Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression, Journal of Infection and Public Health;2018, 11,265–269

Wasti SP, Simkhada P, Randall J, Freeman JV, Van Teijlingen E. Barriers to and facilitators of antiretroviral therapy adherence in Nepal: a qualitative study S. J Health Popul Nutr; 2012;30(4):410–9.

Reda AA, Biadgilign S, Deribew A, Gebre B, Deribe K. Predictors of change in CD4 lymphocyte count and weight among HIV infected patients on anti-retroviral treatment in Ethiopia: a retrospective longitudinal study. PLoS ONE. 2013;8(4)

Kim KH, Yi J, Lee HS. The CD4 slope can be a predictor of immunologic recovery in advanced HIV Patients: a case control study. J Intern Med. 2015;30(5):705.

Viard PJ, Mocroft A, Chiesi A, Kirk O, Røge B, Panos G, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the Euro SIDA study. J Infect Dis. 2001;183:1290-4.

Gea-Banacloche J, LH LC. Immune reconstitution in HIV infection. AIDS. 1999;13(Suppl A):S25–38.

Kwobach CM, Braitstein P, Koech JK, Simiyu G, Mwanqi AW, Siika AM et al. Factors associated with late engagement to HIV care in Western Kenya: a cross-sectional study. J Int Assoc Provid AIDS Care. 2015.

Florence E, Lundgren J, Dreezen C, Fischer M, Kirk O, Blaxhult A, et al.Factors associated with a reduced CD4+ lymphocyte count response to HAART despite full viral suppression in the Euro SIDA study. HIV Med.2003;4(3):255–62.

Smith JC, Sabin AC, Youle SM, Loes KS, Lampe CF, Madge S, et al. Factors influencing increases in CD4 cell counts of HIV positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis. 2004;190:1860–8.

How to cite this article:

Dhananjay Patil, Abdurrahman Helal Ahmed, Mohammed Awais, Sanaurrahman, Rajashri More, Karishma Shrivastav, Rupesh Deore, Vinod Bairagi; Formulation, development and in vitro evaluation of Sildenafil Citrate Lignocaine HCL gel; Panacea Journal of Pharmacy and Pharmaceutical Sciences 2018:7(3);59-70.

Published

2018-09-29

Issue

Section

Original Research Article